Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

Author(s):

Martin David Harp

Key Takeaways

SING IMT improved distance and near vision in AMD patients, with minimal impact on corneal endothelial cell density and manageable safety outcomes.
At 6 months post-surgery, 97.1% of patients achieved at least a 1-line gain in best-corrected distance vision, with significant improvements in near reading ability.
The study involved 35 patients aged 55 or older, who participated in a rehabilitation program to optimize visual outcomes post-surgery.
SING IMT is approved in CE Mark referenced countries, with over 400 patients having received the implant, highlighting its potential to restore vision in AMD patients.

(Image Credit: AdobeStock/tadamichi)

Samsara Vision has reported intermediate-term visual and safety outcomes of the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in patients 6 months post-surgery. According to the company, SING IMT implantation improved distance and near vision, with a low impact on the corneal endothelium cell density and manageable safety outcomes.

Furthermore, results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively. The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months, with distance vision also being improved by ⁓3 lines at 6 months post-surgery.

The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD). Starting 6 weeks after surgery, patients participated in a required rehabilitation program, attending 8 90-minute sessions every 2-to-3 weeks for 6 months to optimize their visual outcomes.

No clinically meaningful change from baseline was measured in intraocular pressure or anterior chamber depth. The mean (SD) change from baseline in corneal endothelial cell density at 6 months in operated eyes was -280.7 (315.9) cells/mm2 (-11.4 %).

"This 6-month review highlights the potential of SING IMT to restore meaningful vision to individuals blinded by AMD, while preserving long-term corneal health with its innovative design," said Prof. Toro, co-author of the study from University Hospital Federico II, Naples, Italy.

The SING MT is approved for use in CE Mark referenced countries, with 19 CE referenced countries having implanted the SING IMT in more than 400 patients.

References:

Samsara Vision Announces Positive Six-Month Visual and Safety Outcomes from the SING IMT^® (Smaller-Incision New-Generation Implantable Miniature Telescope). Press Release. Published January 13, 2025. Accessed January 13, 2025. https://www.businesswire.com/news/home/20250112004584/en/Samsara-Vision-Announces-Positive-Six-Month-Visual-and-Safety-Outcomes-from-the-SING-IMT%C2%AE-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope